Analysis of MSCT imaging features of adrenal ganglioneuroma / 中国基层医药

Objective To discuss MSCT imaging features of adrenal ganglioneuroma ,and to sum up the key points of differential diagnosis .Methods The MSCT manifestations of 8 cases with adrenal ganglioneuroma confirmed by operation and pathology were analyzed combined with relevant literature .Results All adrenal ganglioneuromas were single ,5 cases of right adrenal gland ,3 cases of left adrenal gland ,most tumor density was uniform ,density of soft tissue in 7 cases,speckle calcification was seen in 2 cases.No enhanced or mild enhancement was found in the enhanced posterior artery ,the portal and delayed period showed mild continuous enhancement and line like separation enhancement and encapsulation enhancement .Low density of water samples in 1 case of CT plain scan ,no strengthe-ning at all stages .Conclusion Adrenal ganglioneuroma is rare , the dynamic enhanced performance of MSCT has some characteristics ,and it is beneficial to identify other adrenal tumors .

Initial Experience with Posterior Retroperitoneoscopic Adrenalectomy for the Adrenal Tumors / 대한내분비외과학회지

PURPOSE: Posterior retroperitoneoscopic adrenalectomy (PRA) for small adrenal tumors has recently been in the spotlight due to its several benefits. Compelling advantages for endoscopic surgeons include direct, safe, and fast approach to the adrenal gland without trespass to the intraperitoneal organ. This study reports our initial experiences of PRA for the management of adrenal tumors. METHODS: From December 2009 to August 2011, 63 patients underwent PRA for the management of adrenal tumor. Among these patients, laparoscopic adrenalectomy and robotic adrenalectomy were performed in 54 and nine patients, respectively. We retrospectively reviewed records of all surgical outcomes. RESULTS: Of the 54 patients, 22 were male and 32 were female, and mean age was 51.7±14.0 years. Mean body mass index was 24.6±3.6 kg/m² and mean dimension of the tumors was 2.66±1.36 cm. Six patients were diagnosed with Cushing's disease, 22 patients with primary aldosteronism, seven patients with pheochromocytoma, one patient with metastatic adrenal gland cancer, and 18 patients with nonfunctioning adrenal tumors. Mean operative time was 88.5±27.1 min, mean blood loss was 17.4±37.4 ml, and mean duration to first oral intake was 0.83±0.4 days. Mean number of postoperative analgesics used was 2.28±2.54, and mean postoperative hospital stay was 2.85±1.43 days. There was no open conversion during the operation and no post-operative complication. CONCLUSION: PRA is a safe and fast procedure. In experienced hands, PRA represents one of the ideal approaching methods in the adrenal gland surgery.

I131 MIBG imaging in the diagnosis of pheochromocytoma: Philippine setting

The clinical diagnosis of pheochromocytoma is easy, considering that it manifests as labile hypertension, attacks of palpitations, headache, sweating, pallor or flushing. Urinary VMA or metanephrines seem to be the first investigative step as well as a CT scan to localize it as 85-90 percent arise from the adrenal medulla. Ten percent of these tumors are bilateral but non-adrenal tumors may arise from the sympathetic ganglia, usually alongside the aorta or its branches and in the wall of the urinary bladder. One percent is found outside the abdominal cavity. Meta-iodobenzyl guanidine (MIBG) is an excellent scanning agent that is taken up by most benign and malignant pheochromocytoma tissues. While this procedure is quite costly and underutilized in the Philippines, this paper was done to review its indications and how helpful it can be. From 2001 -2005, I131 MIBG scintigraphy was done only in 17 patients in two medical centers to confirm the diagnosis of pheochromocytoma. The clinicians must be informed that this is not a screening procedure but it is particularly helpful in surveying the entire body for adrenal and extra-adrenal metastatic lesions. It is also diagnostic of intra-adrenal paragangliomas, neuroblastoma, carcinoids, and medullary thyroid carcinoma. This study was, likewise, done with the thought that MIBG may be utilized in the future for therapy as it has shown to be effective in pheochromocytoma and neuroblastoma.

A case of adrenal gland dependent hyperadrenocorticism with mitotane therapy in a Yorkshire terrier dog

Hyperadrenocorticism, a disorder characterized by excessive production of cortisol by the adrenal cortex, is wellrecognized in dogs. A 10-year-old, intact male, Yorkshire terrier dog was evaluated because of corneal ulceration and generalized alopecia. Diagnosis was made based on history taking, clinical signs, physical examination, and results of routine laboratory testing (complete blood count, serum biochemical analysis, and urinalysis). In addition, adrenocorticotropic hormone (ACTH) stimulation test and abdominal ultrasonography were also used to diagnose this case. The patient was diagnosed as adrenal gland neoplasia and medical therapy using the adrenocorticolytic agent, mitotane, was initiated. An ACTH stimulation test was performed after initial therapy. After successful induction was obtained, maintenance therapy with mitotane still continued.

Usefulness of Percentage Enhancement Washout Value Calculated on Unenhanced, Contrast-Enhanced, and Delayed Enhanced CT in Adrenal Masses: Adenoma versus Metastasis

PURPOSE: To determine the usefulness of percentage enhancement washout value calculated on unenhanced, enhanced and delayed enhanced CT scans for the characterization of adrenal masses. MATERIALS AND METHODS: Forty adrenal masses less than 5 cm in size were assessed using a protocol consisting of unenhanced CT, enhanced CT 60 seconds after intravenous administration of contrast material, and delayed enhanced CT at 10 minutes. The CT attenuation value of adrenal tumors was estimated on each scan, and percentage enhancement washout value was calculated as follows: [(attenuation value at enhanced CT-attenuation value at delayed CT)/ (attenuation value at enhanced CT-attenuation value at unenhanced CT)x100]. An adrenal mass was considered benign if its percentage enhancement washout value was at the threshold value, set to 60% and 50%, or higher. The accuracy of the procedure was determined by comparing its findings withthe final clinical diagnosis. RESULTS: Twenty-nine massess were benign and 11 were malignant. The mean percentage enhancement washout value of the former was significantly higher than that of the latter (66.7% vs. 21.8%; p<0.01). All adenomas except one had a washout value of more than 50%. With a percentage washout threshold of 60%, 35 of 40 lesions were correctly characterized as benign or malignant [sensitivity 82.7% (24/29), specificity 100% (11/11), accuracy 87.5% (35/40)]; with a threshold of 50%, 39 of 40 lesions were correctly characterized [(sensitivity 96.5% (28/29), specificity 100% (11/11), accuracy 97.5% (39/40)]. CONCLUSION: Percentage enhancement washout values are useful for characterizing an adrenal mass as benign or malignant. For characterization, a threshold value of 50% was more accurate than one of 60%.